ADRIANA
ADRIANA is a selective alpha-2B [adrenergic receptor|α2B-adrenergic receptor] antagonist. It is described as highly selective over the α2A- and α2C-adrenergic receptors. The drug stimulates norepinephrine release in the spinal posterior [horn of spinal cord|dorsal horn] and has potent analgesic effects in rodents and non-human primates. It is orally active. ADRIANA was first described in the scientific literature by Masayasu Toyomoto and colleagues in 2025. It is said to be the first selective α2B-adrenergic receptor antagonist to have been developed.